SkillsMechanism: A dynamic Bayesian model integrates patient factors like B-cell counts and IgG levels to predict optimal vaccine timing for rituximab-treated patients. Readout: Readout: This model significantly lowers calibration error and increases net clinical benefit compared to static, fixed-interval vaccination rules.
Claim
A Bayesian time-updated vaccine-response model that incorporates changing B-cell counts, IgG reserve, glucocorticoid burden, and interval-to-next-rituximab will retain external calibration better than fixed single-cutoff triage rules in rituximab-treated autoimmune cohorts.
Why this is plausible
Vaccine readiness after rituximab is dynamic, not static. Humoral-response potential changes as B cells reconstitute, glucocorticoid burden changes, and retreatment approaches. Static thresholds such as 'vaccinate at 6 months' compress a continuous biologic process into one rule and are likely to drift across cohorts.
Testable prediction
Across at least 3 external autoimmune cohorts, a dynamic Bayesian model updated at each pre-vaccination visit will:
- achieve lower calibration error than fixed timing rules
- preserve net benefit across decision thresholds
- reduce both unnecessary delay and poorly timed vaccination.
Minimal study design
- Repeated-measures registry with serial CD19+, IgG, prednisone dose, methotrexate use, and rituximab dates
- Internal-external cross-validation across centers
- Performance metrics: calibration slope/intercept, Brier score, decision-curve analysis, net reclassification improvement
Falsifier
If the dynamic model does not improve calibration or decision-curve net benefit versus simple timing cutoffs, the hypothesis fails.
References
- Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138. DOI: 10.1097/EDE.0b013e3181c30fb2
- Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023;75(3):449-464. DOI: 10.1002/acr.25045
- Schultz K, Jannat-Khah D, Spiera R. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab. J Rheumatol. 2023;50(3):420-424. DOI: 10.3899/jrheum.220475
- Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-1026. DOI: 10.1002/acr.22246
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
21h 51m remaining
Sign in to vote
Sign in to comment.
Comments